Capricor Therapeutics Inc. [NASDAQ: CAPR] jumped around 0.46 points on Wednesday, while shares priced at $4.69 at the close of the session, up 10.87%. The company report on November 9, 2020 that Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19.
Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins.
Capricor Scheduling Pre-IND Meeting with FDA to Discuss Clinical Strategy.
Capricor Therapeutics Inc. stock is now 266.41% up from its year-to-date (YTD) trading value. CAPR Stock saw the intraday high of $4.78 and lowest of $4.18 per share. The company’s 52-week high price is 12.32, which means current price is +432.95% above from all time high which was touched on 07/28/20.
Compared to the average trading volume of 1.12M shares, CAPR reached a trading volume of 1310004 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Capricor Therapeutics Inc. [CAPR]?
Maxim Group have made an estimate for Capricor Therapeutics Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on December 26, 2018. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $6.50 to $8.60. The new note on the price target was released on January 26, 2018, representing the official price target for Capricor Therapeutics Inc. stock. Previously, the target price had yet another raise from $2.15 to $6.50, while H.C. Wainwright kept a Buy rating on CAPR stock.
The Average True Range (ATR) for Capricor Therapeutics Inc. is set at 0.30, with the Price to Sales ratio for CAPR stock in the period of the last 12 months amounting to 158.52. The Price to Book ratio for the last quarter was 2.24, with the Price to Cash per share for the same quarter was set at 1.79.
How has CAPR stock performed recently?
Capricor Therapeutics Inc. [CAPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.83. With this latest performance, CAPR shares dropped by -4.29% in over the last four-week period, additionally sinking by -28.40% over the last 6 months – not to mention a rise of 144.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CAPR stock in for the last two-week period is set at 57.34, with the RSI for the last a single of trading hit 64.37, and the three-weeks RSI is set at 50.95 for Capricor Therapeutics Inc. [CAPR]. The present Moving Average for the last 50 days of trading for this stock 4.76, while it was recorded at 4.22 for the last single week of trading, and 4.20 for the last 200 days.
Capricor Therapeutics Inc. [CAPR]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Capricor Therapeutics Inc. [CAPR] shares currently have an operating margin of -769.52. Capricor Therapeutics Inc.’s Net Margin is presently recorded at -760.36.
Return on Total Capital for CAPR is now -84.95, given the latest momentum, and Return on Invested Capital for the company is -83.94. Return on Equity for this stock declined to -133.42, with Return on Assets sitting at -75.06. When it comes to the capital structure of this company, Capricor Therapeutics Inc. [CAPR] has a Total Debt to Total Equity ratio set at 49.36. Additionally, CAPR Total Debt to Total Capital is recorded at 33.05, with Total Debt to Total Assets ending up at 30.38. Long-Term Debt to Equity for the company is recorded at 49.36, with the Long-Term Debt to Total Capital now at 33.05.
Reflecting on the efficiency of the workforce at the company, Capricor Therapeutics Inc. [CAPR] managed to generate an average of -$477,614 per employee. Receivables Turnover for the company is 5.73 with a Total Asset Turnover recorded at a value of 0.10.Capricor Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 19.10 and a Current Ratio set at 19.10.
Earnings analysis for Capricor Therapeutics Inc. [CAPR]
With the latest financial reports released by the company, Capricor Therapeutics Inc. posted -0.43/share EPS, while the average EPS was predicted by analysts to be reported at -0.7/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 38.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CAPR.
Insider trade positions for Capricor Therapeutics Inc. [CAPR]
There are presently around $5 million, or 4.80% of CAPR stock, in the hands of institutional investors. The top three institutional holders of CAPR stocks are: BLACKROCK INC. with ownership of 341,523, which is approximately 900.771% of the company’s market cap and around 0.50% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 198,800 shares of the stock with an approximate value of $0.84 million in CAPR stocks shares; and NORTHERN TRUST CORP, currently with $0.63 million in CAPR stock with ownership of nearly New of the company’s market capitalization.
Positions in Capricor Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 22 institutional holders increased their position in Capricor Therapeutics Inc. [NASDAQ:CAPR] by around 977,250 shares. Additionally, 8 investors decreased positions by around 278,002 shares, while 5 investors held positions by with 25,484 shares. The mentioned changes placed institutional holdings at 1,229,768 shares, according to the latest SEC report filing. CAPR stock had 14 new institutional investments in for a total of 489,362 shares, while 4 institutional investors sold positions of 273,574 shares during the same period.